The CNR1 gene as a pharmacogenetic factor for antipsychotics rather than a susceptibility gene for schizophrenia.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  European Neuropsychopharmacology

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/J.EURONEURO.2007.05.005PMID 17669634
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• No evidence for an involvement of variants in the cannabinoid receptor gene (CNR1) in obesity in German children and adolescents.

  2007cited by this paper
• Introduction on psychopharmacogenetics

  2006cited by this paper
• Psychopharmacogenetics of schizophrenia and psychosis

  2006cited by this paper
• Cannabis receptor haplotype associated with fewer cannabis dependence symptoms in adolescents

  2006cited by this paper
• (AAT)n repeat in the cannabinoid receptor gene (CNR1): association with cocaine addiction in an African-Caribbean population

  2006cited by this paper
• Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction.

  2005cited by this paper
• Applied Logistic Regression: Hosmer/Applied Logistic Regression

  2005cited by this paper
• Effects of cannabidiol in animal models predictive of antipsychotic activity

  2005cited by this paper
• Negative symptoms of schizophrenia could explain discrepant data on the association between the 5-HT2A receptor gene and response to antipsychotics.

  2005cited by this paper
• Hardy–Weinberg equilibrium in genetic association studies: an empirical evaluation of reporting, deviations, and power

  2005cited by this paper
• Depression in Parkinson's disease is related to a genetic polymorphism of the cannabinoid receptor gene (CNR1)

  2005cited by this paper
• Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction.

  2005cited by this paper
• Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people

  2004cited by this paper
• Causal association between cannabis and psychosis: examination of the evidence

  2004cited by this paper
• First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol.

  2004cited by this paper
• The indigenous Pseudomonas plasmid pQBR103 encodes plant-inducible genes, including three putative helicases.

  2004cited by this paper
• Human cannabinoid receptor 1: 5′ exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse

  2004cited by this paper
• Haloperidol, but not clozapine, produces dramatic catalepsy in Δ9‐THC‐treated rats: possible clinical implications

  2003cited by this paper
• [Cannabis and schizophrenia: demographic and clinical correlates].

  2003cited by this paper
• Alcoholism-related phenotypes and genetic variants of the CB1 receptor

  2003cited by this paper
• Association of a CB1 cannabinoid receptor gene (CNR1) polymorphism with severe alcohol dependence.

  2002cited by this paper
• Cannabis and schizophrenia: impact on onset, course, psychopathology and outcomes

  2002cited by this paper
• Association of 5-HT(2A) receptor gene polymorphism with major affective disorders: the case of a subgroup of bipolar disorder with low suicide risk.

  2002cited by this paper
• CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia

  2002cited by this paper
• Endocannabinoids and cannabinoid receptor genetics.

  2002cited by this paper
• Substance abuse and suicidality in schizophrenia: a common risk factor linked to impulsivity.

  2001cited by this paper
• Schizophrenia and the cannabinoid receptor type 1 (CB1): association study using a single-base polymorphism in coding exon 1.

  2001cited by this paper
• Association study between cannabinoid receptor gene (CNR1) and pathogenesis and psychotic symptoms of mood disorders.

  2001cited by this paper
• Pharmacogenetics of clozapine response

  2000cited by this paper
• No association between (AAT)n repeats in the cannabinoid receptor gene (CNR1) and heroin abuse in a Chinese population

  2000cited by this paper
• No evidence for association of serotonin-2A receptor variant (102T/C) with schizophrenia or clozapine response in a Chinese population.

  1999cited by this paper
• A frequent polymorphism in the coding exon of the human cannabinoid receptor (CNR1) gene.

  1999cited by this paper
• Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine

  1998cited by this paper
• Cannabinoid receptor gene (CNR1): association with IV drug use

  1997cited by this paper
• Suggestive evidence for a schizophrenia susceptibility locus on chromosome 6q and a confirmation in an independent series of pedigrees.

  1997cited by this paper
• Morbid risk of schizophrenia for relatives of patients with cannabis-associated psychosis.

  1995cited by this paper
• Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative.

  1994cited by this paper
• Current cannabis use and tardive dyskinesia.

  1993cited by this paper
• At Issue: Defining Treatment Refractoriness in Schizophrenia

  1990cited by this paper
• Defining treatment refractoriness in schizophrenia.

  1990cited by this paper
• Cannabis and schizophrenia. A longitudinal study of Swedish conscripts.

  1987cited by this paper
• A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS

  1970cited by this paper
• Tests for Linear Trends in Proportions and Frequencies

  1955cited by this paper

• Epigenetic Control in Schizophrenia.

  2025cites this paper
• G protein-coupled receptor (GPCR) pharmacogenomics

  2024cites this paper
• Cannabinoid receptor gene CNR1 is downregulated in subcortical brain samples and upregulated in blood samples of individuals with schizophrenia: A participant data systematic meta‐analysis

  2023cites this paper
• Epigenome-wide studies of antipsychotics: a systematic review and pathway meta-analysis.

  2023cites this paper
• Cannabinoid receptor type 2 gene is associated with comorbidity of schizophrenia and cannabis dependence and fatty acid amide hydrolase gene is associated with cannabis dependence in the Spanish population

  2023cites this paper
• Potential of olfactory neuroepithelial cells as a model to study schizophrenia: A focus on GPCRs (Review)

  2023cites this paper
• Cannabis Use and Endocannabinoid Receptor Genes: A Pilot Study on Their Interaction on Brain Activity in First-Episode Psychosis

  2023cites this paper
• Cannabinoid-Based Medicine: Pharmacology and Drug Interactions

  2022cites this paper
• Peripheral biomarkers of treatment-resistant schizophrenia: Genetic, inflammation and stress perspectives

  2022influential citation
• HU-910, a CB2 receptor agonist, reverses behavioral changes in pharmacological rodent models for schizophrenia.

  2022cites this paper
• Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders

  2022influential citation
• Polymorphisms in Schizophrenia-Related Genes Are Potential Predictors of Antipsychotic Treatment Resistance and Refractoriness

  2022cites this paper
• Genetic Testing for Antipsychotic Pharmacotherapy: Bench to Bedside

  2021cites this paper
• Cannabinoid receptor type‐1 and its correlation with CB1 gene polymorphism‐1359G/A in ectopic pregnancy compared to the control group

  2021cites this paper
• Gene-Environment Interactions in Schizophrenia: A Literature Review

  2021cites this paper
• Cannabinoid receptor type 2 gene is associated with comorbidity of schizophrenia and cannabis dependence and fatty acid amide hydrolase gene is associated with cannabis dependence in the Spanish population.

  2021cites this paper
• Progress in Genetic Polymorphisms Related to Lipid Disturbances Induced by Atypical Antipsychotic Drugs

  2020cites this paper
• Are CB2 Receptors a New Target for Schizophrenia Treatment?

  2020cites this paper
• Impact of Endocannabinoid System Manipulation on Neurodevelopmental Processes Relevant to Schizophrenia.

  2020cites this paper
• Endocannabinoid System Components as Potential Biomarkers in Psychiatry

  2020cites this paper
• Psychosis and synthetic cannabinoids.

  2018cites this paper
• The endocannabinoid system in mental disorders: Evidence from human brain studies

  2018cites this paper
• Endocannabinoids: Molecular, Pharmacological, Behavioral and Clinical Features

  2018cites this paper
• Accessing Gene Expression in Treatment-Resistant Schizophrenia

  2018cites this paper
• The Endocannabinoid System and Human Brain Functions: Insight From Memory, Motor, and Mood Pathologies

  2017cites this paper
• The role of the CNR1 gene in schizophrenia: a systematic review including unpublished data

  2017cites this paper
• Cannabinoid Receptor Type 1 and mu-Opioid Receptor Polymorphisms Are Associated With Cyclic Vomiting Syndrome

  2017cites this paper
• An Introduction to the Endogenous Cannabinoid System.

  2016cites this paper
• Future perspectives: Cannabinoid CB2 receptor ligands and their therapeutic potential in mental diseases

  2015cites this paper
• Cannabinoid Receptor 1 (CNR1) Gene Polymorphisms in Schizophrenia Patients: Rs6454674 Polymorphism is Associated with Disease Severity

  2015cites this paper
• Interictal psychosis following temporal lobe surgery: dentate gyrus pathology

  2014cites this paper
• Genetic association analysis of CNR1 and CNR2 polymorphisms with schizophrenia in a Korean population

  2014cites this paper
• Pharmacogenetics of the G protein-coupled receptors.

  2014cites this paper
• Cannabinoid Receptor Gene Variations in Drug Addiction and Neuropsychiatric Disorders

  2013cites this paper
• Investigation of endocannabinoid system genes suggests association between peroxisome proliferator activator receptor-α gene (PPARA) and schizophrenia.

  2013cites this paper
• Phencyclidine-Induced Social Withdrawal Results from Deficient Stimulation of Cannabinoid CB1 Receptors: Implications for Schizophrenia

  2013cites this paper
• Medical use of cannabis. Cannabidiol: a new light for schizophrenia?

  2013cites this paper
• Evidence for the involvement of cannabinoid receptors' polymorphisms in the pathophysiology of human diseases

  2013cites this paper
• The endocannabinoid system and its role in schizophrenia: a systematic review of the literature.

  2012cites this paper
• Reversible Disruption of Pre-Pulse Inhibition in Hypomorphic-Inducible and Reversible CB1-/- Mice

  2012cites this paper
• Contributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence.

  2012cites this paper
• Antipsychotic-like effects of cannabidiol and rimonabant: systematic review of animal and human studies.

  2012cites this paper
• Recent advances in targeting the ionotropic glutamate receptors in treating schizophrenia.

  2012cites this paper
• Kannabinoid tip 1 reseptör (CB1) ve terapötik yaklaşımlara genel bakış-II

  2012cites this paper
• Második generációs antipszichotikum a szkizofrénia hosszútávú kezelésében

  2012cites this paper
• Contributions of Glutamate and GABA Systems to the Neurobiology and Treatment of Schizophrenia

  2011cites this paper
• Endocannabinoid System and Psychiatry: In Search of a Neurobiological Basis for Detrimental and Potential Therapeutic Effects

  2011cites this paper
• Pharmacogenetics of new analgesics

  2011cites this paper
• Cannabis involvement in individuals with bipolar disorder.

  2011cites this paper
• Genome-Wide Pharmacogenomic Study of Neurocognition As an Indicator of Antipsychotic Treatment Response in Schizophrenia

  2011cites this paper
• Toward understanding genetic risk for differential antipsychotic response in individuals with schizophrenia

  2011cites this paper
• Psychopharmacological comparison of schizophrenia spectrum disorder with and without cannabis dependency.

  2011cites this paper
• Pharmacogenetics of Response to Antipsychotics in Patients with Schizophrenia

  2011cites this paper
• Investigação dos genes CNR1 e AKT1 como possíveis fatores de risco/proteção para a esquizofrenia.

  2011cites this paper
• Cognitive Control Deficits in Schizophrenia: Mechanisms and Meaning

  2011cites this paper
• The promise and reality of pharmacogenetics in psychiatry.

  2010cites this paper
• Endocannabinoids and Schizophrenia

  2010cites this paper
• [Behavioral, cognitive and psychophysiological effects of cannabinoids: relevance to psychosis and schizophrenia].

  2010cites this paper
• Influence de la consommation de substances sur l'émergence et l'évolution des troubles psychotiques: le cas du cannabis

  2010cites this paper
• Association of polymorphisms of the cannabinoid receptor (CNR1) and fatty acid amide hydrolase (FAAH) genes with heroin addiction: impact of long repeats of CNR1

  2010cites this paper
• Vulnerability Factors for the Psychiatric and Behavioral Effects of Cannabis

  2010cites this paper
• The endocannabinoid system and psychiatric disorders.

  2010cites this paper
• The G1359A-CNR1 gene polymorphism is associated to glioma in Spanish patients

  2010cites this paper
• The promise and reality of pharmacogenetics in psychiatry.

  2010cites this paper
• Advances in the Management of Treatment- Resistant Schizophrenia

  2010cites this paper
• Cannabinoid receptors in brain: pharmacogenetics, neuropharmacology, neurotoxicology, and potential therapeutic applications.

  2009cites this paper
• Pharmacogenomic Biomarkers in Neuropsychiatry: The Path to Personalized Medicine in Mental Disorders

  2009cites this paper
• Role of cannabis and endocannabinoids in the genesis of schizophrenia

  2009influential citation
• Es realmente el consumo de cannabis un factor de riesgo para la esquizofrenia

  2009cites this paper
• Endocannabinoid receptor pharmacology.

  2009cites this paper
• CNR1 Gene is Associated with High Neuroticism and Low Agreeableness and Interacts with Recent Negative Life Events to Predict Current Depressive Symptoms

  2009cites this paper
• Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment

  2009cites this paper
• The implication of CNR1 gene's polymorphisms in the modulation of endocannabinoid system effects.

  2009cites this paper
• Current evidence for a modulation of low back pain by human genetic variants

  2009cites this paper
• The endocannabinoid system and the regulation of neural development: potential implications in psychiatric disorders

  2009cites this paper
• Genomewide Pharmacogenomic Analysis of Response to Treatment with Antipsychotics

  2009cites this paper
• CB1 Expression Is Attenuated in Fallopian Tube and Decidua of Women with Ectopic Pregnancy

  2008cites this paper
• [Role of genetics in psychiatric treatment].

  2008cites this paper
• Динамика когнитивных функций у пациентов с резистентными депрессиями при применении электросудорожной терапии и циклической транскраниальной магнитной стимуляции

  2006cites this paper